



SCRIPT

Medicines Management Newsletter

NHS

Wiltshire

Clinical Commissioning Group

Issue 130

January 2019

Intranet site : <https://prescribing.wiltshireccg.nhs.uk>

To contact NHS Wiltshire CCG Medicines Management Team: ✉ prescribingwiltshire@nhs.net ☎ 01380 733881

ACTIONS this month:-

- GPs and Independent Prescribers can follow these online courses to further develop their skills in antibiotic prescribing and raising antimicrobial stewardship strategies for their clinical teams
- GPs/Practice nurses to review use and prescribing of Barrier Creams
- GPs to review Naproxen and NSAID prescribing re intermittent Naproxen shortage
- GPs to review patients taking Cilest and switch to alternate equivalent brands

TARGET antibiotics: Prescribing in Primary Care Future Learn e-Learning

The course aims to help primary care professionals target the use of antibiotics, in order to help prevent the increase in antimicrobial resistance. By the end of the course individuals will have an understanding of how to apply practical antimicrobial stewardship strategies in their practice.

Week 1 commences on **Monday 28th January 2019**; a new topic will be released every week for the next **7 weeks** and each topic takes **approximately 1 hour**.

<https://www.futurelearn.com/courses/target-antibiotics>

ACTION: GPs and Independent Prescribers can follow these online courses to further develop their skills in antibiotic prescribing and raising antimicrobial stewardship strategies for their clinical teams

Barrier Creams on prescription in Primary Care

We have recently received a number of queries with regards to the choice of product for patients with IAD (Incontinence Associated Dermatitis) and similar conditions requiring barrier creams.

Prophylaxis:

- Use non-soap cleanser or soap substitute to cleanse skin.
- Secura D barrier cream/Aproderm (FP10).

While in hospital, patients may be treated with Secura D barrier cream. Secura D contains 5% dimeticone, is only obtainable via NHS Supply chain and cannot be prescribed on FP10.

Please note Secura Extra protective (containing Zinc Oxide) is not equivalent to Secura D and should not be prescribed.

The correct barrier cream recommended for prescribing in primary care on an FP10 is Aproderm Barrier Cream (£5.50 / 100g)

ACTION: GPs/Practice nurses to review use and prescribing of Barrier Creams

Naproxen shortage

Among the current medicines shortages, the intermittent supply of standard release Naproxen tablets 250mg and 500mg seems to be causing the most problems.

Unfortunately, the CCG has neither influence on stock levels nor any additional information as to when stock levels will be adequately restored. Below are some recommendations which practices may wish to put in place to help deal with this particular situation.

- Inform patients of the shortage and advise to buy Ibuprofen OTC while shortage lasts.
- It is generally accepted that
 - Naproxen 250mg BD dose is approximately equivalent to Ibuprofen 200mg TDS
 - Naproxen 500mg BD dose is approximately equivalent to Ibuprofen 400mg TDS
- Liaise with local pharmacies and agree that they may dispense 250mg tablets if 500mg not available or vice versa, and send script back for amendment retrospectively so as to avoid any delay with patients having to obtain a replacement script.
- If Ibuprofen does not help and no standard Naproxen available, GPs may wish to prescribe gastro-resistant tablets as a one-off replacement, but note that these are comparatively costly.

Diclofenac and all other NSAIDs (-coxibs, -oxicams...) have a less favorable safety profile than Ibuprofen and Naproxen, therefore should only be used as a last resort for patients unable to obtain Naproxen.

Patients may also want to consider purchasing anti-inflammatory gels OTC and should be advised to optimise their Paracetamol dose when appropriate to maximise pain relief. Refer to [NSAID safety audit](#).

ACTION: GPs to review Naproxen and NSAID prescribing re intermittent Naproxen shortage

Formulary Update

Formulary	Drug	Decision	Comments
3Ts	Lidocaine Patches	Red	
3Ts	Dymista nasal spray (Fluticasone/Azelastine)	Green	
BCAP	Esmya® (Ulipristal Acetate)	Amber with SCA	SCA has been amended to reflect recent safety recommendations

Cilest to be discontinued July 2019

The manufacturer of Cilest® (Norgestimate + Ethinylestradiol) advises that this product will be discontinued with effect from July 2019.

The letter states this is a commercial decision and it is stressed that there are no safety, efficacy or quality issues with the product. Current supplies are expected to last until mid-July 2019.

There are two alternative products that are currently available in the UK with the same active ingredients - Cilique® and Lizinna®.

Arden's has created a search on TPP that practices can run to identify all patients currently taking Cilest® so they can have their prescription changed to one of the alternative brands

ACTION: GPs to review patients taking Cilest and switch to alternate equivalent brands

- ▶ Local Reports (8399)
- ▶ Arden's Ltd (14704)
 - ▶ Best Practice
 - ▶ CAS and Alerts
 - ▶ Contracts 2017 to 2018
 - ▶ Contracts 2018 to 2019
 - ▶ Contracts 2018 to 2019 CQRS
 - ▶ Cost Savings
 - Analgesia (7)
 - Cardiovascular (3)
 - Dermatology (6)
 - Diabetes (4)
 - Issues (2)
 - OTC Prescriptions (17)
 - Other (6)

TPP enhancements – Please vote for them!

Two locally requested TPP developments need votes to become reality, could practice staff please support these if considered useful

- Irregular Medication - needs warning if issued too early. Ref 5c120000
Add the same prompt that appears stating that the medication is not due until a specific date to highlight that it is too early.
- One-off pharmacy nomination. Ref 35c20000
Implement an option to nominate a pharmacy as a "one-off" only, rather than making it a permanent choice.

Please contact MMT if you would like to support these but do not know how

VSL3 & VIVOMIXX can no longer be prescribed

ACBS recently reviewed products VSL3 and Vivomixx for continued inclusion in Part XV of the Drug Tariff. The Committee concluded that the evidence did not sufficiently demonstrate that the products are clinically effective. On this basis, both products have been removed.

Patients can purchase OTC to continue using them.

Website Updates

Cannabis prescribing – FAQs	https://prescribing.wiltshireccg.nhs.uk/?wpdmdl=1792
Management of Glaucoma in Primary Care (Adults)	https://prescribing.wiltshireccg.nhs.uk/?wpdmdl=1793
RCGP - Cannabis based medicines: Desktop guide	https://prescribing.wiltshireccg.nhs.uk/?wpdmdl=1796
Wiltshire formularies traffic light summary – January 2019 version (please destroy old versions)	https://prescribing.wiltshireccg.nhs.uk/?wpdmdl=979
TARGET Antibiotic Toolkit	https://prescribing.wiltshireccg.nhs.uk/?wpdmdl=88
Diagnosis of UTI: quick reference guide	https://prescribing.wiltshireccg.nhs.uk/?wpdmdl=1701
TARGET UTI Leaflet	https://prescribing.wiltshireccg.nhs.uk/?wpdmdl=1695
Treat your infection: UTI - older adults & carers	https://prescribing.wiltshireccg.nhs.uk/?wpdmdl=1794
Treat your infection: RTI	https://prescribing.wiltshireccg.nhs.uk/?wpdmdl=1795
NICE Antibiotic Guidance Summaries	https://prescribing.wiltshireccg.nhs.uk/prescribing-guidance-by-bnf-chapter/infections
Allergic rhinitis in Adults guidance 2018	https://prescribing.wiltshireccg.nhs.uk/?wpdmdl=1805
Prescribing Guidelines for Dry Eye	https://prescribing.wiltshireccg.nhs.uk/?wpdmdl=1806